Kengo Watanabe

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models

Ryohei Katayama, Bo Gong, Noriko Togashi et al. · Nature Communications · 2019 · 141 citations · Full text

Medicine, Oncology, Pharmacology +15

Predictability of Idiosyncratic Drug Toxicity Risk for Carboxylic Acid-Containing Drugs Based on the Chemical Stability of Acyl Glucuronide

Ryoko Sawamura, Noriko Okudaira, Kengo Watanabe et al. · Drug Metabolism and Disposition · 2010 · 127 citations

Pharmacy, Pharmacology, Toxicology +17

Single-Master Dual-Slave Surgical Robot With Automated Relay of Suture Needle

Kengo Watanabe, Takahiro Kanno, Kazuhisa Ito et al. · IEEE Transactions on Industrial Electronics · 2018 · 51 citations

Engineering, Robotics Engineering, Surgery +15

Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part II: Exploration of 6–6 fused rings as alternative S1 moieties

Kenji Yoshikawa, Shozo Kobayashi, Yumi Nakamoto et al. · Bioorganic & Medicinal Chemistry · 2009 · 43 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models

Makiko Yamada, Shinichi Inoue, Daisuke Sugiyama et al. · Drug Metabolism and Disposition · 2020 · 20 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17